South-South Pharma Strategy in BRICS+: Rebuilding Global Supply Chains Through Strategic Coordination

The global pharmaceutical landscape is undergoing a structural shift—and BRICS+ is emerging as a decisive force shaping its future. This report provides a comprehensive analysis of how South-South cooperation in pharmaceutical manufacturing is transforming global supply chains, reducing dependency on Western systems, and strengthening strategic autonomy across emerging economies.

Focusing on key developments such as API expansion, vaccine production capabilities, and the rise of distributed manufacturing networks across Asia, Africa, and the Middle East, the report highlights how BRICS+ nations are leveraging industrial policy, capital investments, and logistics integration to create a resilient pharmaceutical ecosystem. It examines the role of major actors including India, China, Gulf economies, and African manufacturing hubs in reshaping access to essential medicines and healthcare technologies.

The analysis also addresses critical challenges including regulatory fragmentation, geopolitical competition, and gaps in advanced biotechnology capabilities, while outlining future scenarios for coordinated growth and institutional alignment.

If you are not tracking this shift in global pharmaceutical power, you risk missing one of the most important transformations in economic governance. Follow Global Eye Intelligence for expert insights on BRICS+, pharma strategy, global health supply chains, biotechnology, emerging markets, and geopolitical economics.